Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit⁺ Cardiac Stem Cells As Regenerative Therapy for Heart Failure).

ABSTRACT:

Rationale

Autologous bone marrow mesenchymal stem cells (MSCs) and c-kit⁺ cardiac progenitor cells (CPCs) are 2 promising cell types being evaluated for patients with heart failure (HF) secondary to ischemic cardiomyopathy. No information is available in humans about the relative efficacy of MSCs and CPCs and whether their combination is more efficacious than either cell type alone.

Objective

CONCERT-HF (Combination of Mesenchymal and c-kit⁺ Cardiac Stem Cells As Regenerative Therapy for Heart Failure) is a phase II trial aimed at elucidating these issues by assessing the feasibility, safety, and efficacy of transendocardial administration of autologous MSCs and CPCs, alone and in combination, in patients with HF caused by chronic ischemic cardiomyopath

SUBMITTER: Bolli R 

PROVIDER: S-EPMC5993622 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature